Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02858310 · OUTCOME

Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR)

E7 TCR T Cells for Human Papillomavirus-Associated Cancers · Source last updated 2026-03-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
At 12 weeks, every 3 months x 3, and every 6 months for approximately 5 years

What was measured

Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Compete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.

Analysis population: Participants in Phase II only were evaluable for this outcome.

Groups in this outcome

Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells

Phase II Cohort; Arm 2: Phase II; 1 x 10\^11 E7 Cells that were determined in Phase I + Aldesleukin.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells18

Reported measurements

Complete Response
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells0Not reportedNot reportedNot reportedNot reported
Partial Response
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells5Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Complete Response
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        5
    title
    Partial Response
denoms
  1. counts
    1. group Id
      OG000
      value
      18
    units
    Participants
description
Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Compete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.
groups
  1. description
    Phase II Cohort; Arm 2: Phase II; 1 x 10\^11 E7 Cells that were determined in Phase I + Aldesleukin.
    id
    OG000
    title
    Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells
param Type
COUNT_OF_PARTICIPANTS
population Description
Participants in Phase II only were evaluable for this outcome.
reporting Status
POSTED
time Frame
At 12 weeks, every 3 months x 3, and every 6 months for approximately 5 years
title
Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR)
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice